To evaluate the therapeutic value of mirikizumab in IBD, researchers conducted a systematic review and meta-analysis of ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Guselkumab significantly improves clinical remission rates in patients with active ulcerative colitis, according to phase 3 data.

Hunter Renfrow is mounting an NFL comeback after spending the 2024 season out of the league battling ulcerative colitis. Here ...

Research shows that smoking may have beneficial effects on symptoms of ulcerative colitis. But the risks of starting this ...

Stroke and coronary artery disease were the primary causes linked to the deaths of all participants with autoimmune disease, ...

Finding a cure for inflammatory bowel disease (IBD) would mean reducing treatment waste, according to Ashwin N.

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrierData presented at Digestive Disease Week in San ...

Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately-to-severely active ulcerative colitis: San Diego, California Tuesday, May 6, 2 ...

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC ...

CHARLOTTE, N.C. -- Wide receiver Hunter Renfrow dropped from 185 pounds to 150 pounds last year while being treated for ulcerative colitis, which played a big role in his decision to step away ...